Simulations Plus (NASDAQ:SLP) Announces Quarterly Earnings Results

Simulations Plus (NASDAQ:SLP) issued its earnings results on Tuesday. The technology company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.15 by $0.04, Briefing.com reports. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm had revenue of $18.54 million during the quarter, compared to the consensus estimate of $17.92 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. The business’s quarterly revenue was up 14.2% on a year-over-year basis. Simulations Plus updated its FY24 guidance to $0.54-0.56 EPS and its FY 2024 guidance to 0.540-0.560 EPS.

Simulations Plus Price Performance

NASDAQ:SLP opened at $39.89 on Thursday. The firm’s 50 day simple moving average is $47.68 and its 200 day simple moving average is $44.15. The company has a market cap of $797.40 million, a PE ratio of 75.26 and a beta of 0.72. Simulations Plus has a one year low of $32.69 and a one year high of $52.69.

Simulations Plus Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 5th. Shareholders of record on Monday, July 29th will be issued a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Monday, July 29th. Simulations Plus’s dividend payout ratio is presently 45.28%.

Analysts Set New Price Targets

Several brokerages have issued reports on SLP. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price target on shares of Simulations Plus in a research report on Wednesday. William Blair started coverage on shares of Simulations Plus in a research note on Friday, June 28th. They issued an “outperform” rating for the company. Finally, Oppenheimer boosted their price objective on shares of Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 13th.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total transaction of $919,000.00. Following the completion of the sale, the director now owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Daniel L. Weiner sold 750 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $49.32, for a total transaction of $36,990.00. Following the transaction, the director now directly owns 7,009 shares of the company’s stock, valued at $345,683.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $45.95, for a total value of $919,000.00. Following the completion of the sale, the director now directly owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The disclosure for this sale can be found here. In the last quarter, insiders have sold 44,500 shares of company stock worth $2,072,198. Insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.